Chondrogard, Ampoules 100mg/ml, 2ml, 25pcs

Composition

>

1 ml of solution for injection contains:

Active ingredient:

chondroitin sodium sulfate – 100 mg.

Auxiliary substances:

benzyl alcohol-9 mg,

sodium disulfite-1 mg,

sodium hydroxide – up to pH 6.0-7.5,

d/i water – up to 1 ml

Pharmacological action

Pharmacodynamics

A high-molecular mucopolysaccharide that affects metabolic processes in hyaline cartilage. Reduces degenerative changes in the cartilage tissue of joints, accelerates the processes of its recovery, and stimulates the synthesis of proteoglycans. When treated with the drug, soreness decreases and mobility of the affected joints improves.

In the treatment of degenerative joint changes with the development of secondary synovitis, a positive effect can be observed as early as 2-3 weeks after the start of drug use: joint pain decreases, the clinical manifestations of reactive synovitis disappear, and the volume of movement in the affected joints increases. The therapeutic effect persists for a long time after the end of the course of treatment. mica

Pharmacokinetics

After intramuscular use, chondroitin sulfate is rapidly distributed. Within 30 minutes after the injection, it is detected in the blood in significant concentrations. The maximum concentration (C_max) of chondroitin sulfate in plasma is reached after 1 h, then gradually decreases over 2 days.

Chondroitin sulfate accumulates mainly in the cartilage tissue of the joints. The synovial membrane is not an obstacle to the penetration of the drug into the joint cavity. Experiments have shown that 15 minutes after intramuscular injection of chondroitin sulfate is detected in the synovial fluid, then penetrates into the articular cartilage, where its Cmax is reached after 48 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of the peripheral joints;
• intervertebral osteochondrosis and osteoarthritis;
• to accelerate the formation of bone callus in fractures.

Contraindications

• Hypersensitivity to the drug or to its components;
• bleeding and a tendency to bleeding;
• thrombophlebitis;
• childhood;
• pregnancy and lactation (data on the safety of the drug are currently unavailable).

Side effects

Allergic reactions:  pruritus, erythema, urticaria, dermatitis, hemorrhages at the injection site.

Interaction

It is possible to increase the effect of indirect anticoagulants, antiplatelet agents, and fibrinolytics, which requires more frequent monitoring of blood clotting parameters when used together.

How to take, course of use and dosage

The drug is prescribed intramuscularly at 100 mg every other day.

If well tolerated, the dose is increased to 200 mg, starting with the fourth injection.

The course of treatment is 25-30 injections. If necessary, a second course of treatment is possible after 6 months.

For the formation of a bone callus, the course of treatment is 3-4 weeks (10-14 injections every other day).

Overdose

Currently, no cases of overdose of chondroitin sulfate have been reported.

Special instructions

Application in pediatrics

There are currently no data on the efficacy and safety of chondroitin sulfate in children.

Form of production

Solution for injection.

Storage conditions

The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25°C.

Shelf

life is 3 years.

Active ingredient

Chondroitin sulfate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Osteochondrosis, Osteoarthritis, Arthritis, Osteoarthritis